CLDX · Celldex Therapeutics, Inc.

The thesis

Celldex Therapeutics has a replicated Phase 3 efficacy result for barzolvolimab in chronic spontaneous urticaria (CSU), but the shares remain well below their high. The adjusted close of $29.37 on 21 October 2026 is 34.5% under the 52-week high of $44.87. The fuller safety disclosure and the 2027 biologics license application (BLA) plan staying on schedule settle whether the decline is over.

The narrative is maturing: the 22 September 2026 readout answered the efficacy question, and the open issue is how the market values it. Both EMBARQ-CSU trials met their Week 12 primary and all key secondary endpoints in Celldex's 22 September 2026 release. HC Wainwright raised its price target to $64 on 2 October 2026, from $42 on 15 June 2026, and the shares still closed lower. Since the 8 October 2026 close of $29.30, the shares have held near that level, and the 14-day relative strength index (RSI) has risen from 18.4 to 39.7.

Bullish and bearish views on Celldex Therapeutics, Inc.

The bull case on Celldex Therapeutics, Inc. (CLDX), in brief: Both pivotal trials met their endpoints. The bear case: The shares fell after good news.

Bull case

• Both pivotal trials met their endpoints. Celldex reported on 22 September 2026 that both tested doses met the Week 12 primary and all key secondary endpoints in EMBARQ-CSU1 and EMBARQ-CSU2. A later disclosure that revises those results would break this point.

• Analysts raised targets after the data. HC Wainwright set a $64 target on 2 October 2026. Benzinga's target record shows Leerink Partners at $88 and Morgan Stanley at $57 as of 23 September 2026.
• Cash covers the filing plan. Celldex reported $717.6 million in cash, cash equivalents and marketable securities at 30 June 2026 and guided funding through 2028. A shorter runway in a later quarterly report would weaken this.
• Durability data exist. At the EAACI meeting on 14 June 2026, Celldex reported that up to 64% of barzolvolimab-treated CSU patients in a Phase 2 study stayed angioedema-free seven months after the last dose.

Bear case

• The shares fell after good news. The close dropped from $36.90 on 11 September 2026 to $31.10 on 25 September 2026 and $29.37 on 21 October 2026. The three-month price change was -16.8% as of 21 October 2026.
• Safety detail is thin. The 22 September 2026 release described safety through Week 24 but gave no adverse-event table. A fuller table showing higher discontinuations or clinically significant toxicity would hurt the regulatory and commercial case.
• Efficacy has not carried into other indications. Celldex stopped the prurigo nodularis Phase 2 study on 21 July 2026 after it missed its primary and key secondary endpoints.
• The recovery is shallow. The close of $29.37 on 21 October 2026 is below the $31.10 close of 25 September 2026 and has not regained the $35 level lost that day.

Price setup

The adjusted daily close was $29.37 on 21 October 2026, 34.5% below the 52-week high of $44.87. The 14-day RSI of 39.7 is out of the extreme oversold zone of 18.4 recorded on 8 October 2026, so selling pressure has eased without a clear recovery in price.

No SEC filings and no company news appear in the period since the prior note, so there is no sign of insider selling or share issuance into the weakness. Retail attention is not measurable from the available sources. The next earnings report, estimated for 10 November 2026, falls inside 30 days.

Catalysts, next 30 days

• ~10 November 2026, est.: Third-quarter 2026 results. A third-party earnings calendar lists this date; Celldex has not confirmed it. The report updates cash against $717.6 million at 30 June 2026 and shows whether the 2027 BLA plan and funding through 2028 hold.
• ~31 December 2026, est. (outside the 30 days): Atopic dermatitis Phase 2 topline, which Celldex guided to late 2026. It tests whether mast-cell depletion works outside urticaria.

What would change the view

The case breaks if the Phase 3 safety table shows clinically significant toxicity or elevated discontinuations, or if Celldex says the CSU BLA will not be filed in 2027. A weak atopic dermatitis result in late 2026 would also narrow the story to one indication. On price, a daily close below $26 would extend the post-readout decline and end the case. A safety table in line with the favorable Week 24 description, together with closes back above the $31.10 level of 25 September 2026, would strengthen it.

What it trades with

Celldex trades on its own trial results more than on any sector move. Its price path since 22 September 2026 diverged from analyst targets, which HC Wainwright, Leerink Partners and Morgan Stanley set at $64, $88 and $57. Other clinical-stage immunology companies with mast-cell or urticaria programs are the nearest read-across for competitive news. No theme grouping currently carries the name.